Home / Market News / $PACB

$PACB news and market catalysts

The 14 most recent market catalysts affecting $PACB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

14 catalysts 3 high impact 8 bullish 4 bearish Biotechnology
Nov 11, 2026 Corporate Catalyst Bullish Impact 65
Pacific Biosciences of California, Inc. Announces $100 Million At-the-Market Equity Offering
Pacific Biosciences of California (PacBio) has announced a new at-the-market (ATM) equity offering program, allowing them to sell up to $100 million in common stock. This move prov…
Nov 9, 2026 Corporate Catalyst Bearish Impact 55
UBS Adjusts Price Target on Pacific Biosciences of California
UBS updated its outlook on Pacific Biosciences of California, adjusting its price target from $3.05 to $2.70, while keeping a Neutral rating. This move comes after the company's Q3…
Nov 6, 2026 Corporate Catalyst Bearish Impact 85
PacBio Reports Third-Quarter 2026 Financial Results and Restructuring
PacBio announced its third-quarter 2026 financial results, showing a 5.5% increase in revenue but a 15% decline in gross profit due to higher costs. This indicates underlying opera…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Maintains Neutral Rating on PacBio, Raises Price Target
Piper Sandler, a prominent investment bank, updated its coverage on Pacific Biosciences of California, Inc. (PacBio). While maintaining a 'Neutral' rating, the firm significantly r…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Underweight Rating on PacBio, Raises Price Target
Barclays maintained its 'Underweight' rating on Pacific Biosciences of California, Inc. (PacBio), signaling continued caution about the stock's prospects. However, the firm simulta…
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
Pacific Biosciences and GeneDx Announce Strategic Partnership
Pacific Biosciences has partnered with GeneDx to integrate its long-read whole genome sequencing technology into GeneDx's diagnostic suite. This is a significant development for PA…
Nov 4, 2026 Corporate Catalyst Neutral Impact 92
PacBio Reports Third-Quarter 2026 Financial Results
PacBio announced its Q3 2026 financial results, reporting $40.6 million in revenue. This is a direct financial update for the company, indicating its performance over the last quar…
Oct 31, 2026 Corporate Catalyst Bullish Impact 55
ARK Invest Increases Holdings in Pacific Biosciences
ARK Invest, through its actively managed ETFs ARKG and ARKK, significantly increased its holdings in Pacific Biosciences (PACB). This action signals ARK's continued conviction in t…
Oct 24, 2026 Corporate Catalyst Bullish Impact 55
Stephens Maintains Buy Rating and Raises Price Target for PacBio
Stephens analyst Mason Carrico has reaffirmed a 'Buy' rating for Pacific Biosciences (PacBio) and raised the price target from $2.00 to $2.50. This action signals continued confide…
Oct 19, 2026 Corporate Catalyst Bullish Impact 65
PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform
PacBio and Verily Health have entered a multi-year strategic collaboration to integrate PacBio's HiFi sequencing with Verily's governed data and AI platform. This partnership is si…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Pacific Biosciences Of California Approves Restructuring Plan To Align With Strategic Initiatives; Restructuring To Reduce Workforce By About 8%; Expects $30M-$40M Annualized Operating Expense Reduction By End Of 2027; Estimates $2M Pre-Tax Charges For Reduction In Force
Pacific Biosciences of California (PACB) is implementing a significant restructuring plan, including an 8% workforce reduction, to better align its resources with strategic initiat…
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (PACB) has announced a reduction in its sales guidance for fiscal year 2026, moving from an initial range of $165 million-$175 million to a new range of $155 mi…
Aug 5, 2026 Corporate Catalyst Neutral Impact 75
Pacific Biosciences of California Appoints Mark Van Oene As President, CEO, Effective Immediately, Succeeding Christian Henry
Pacific Biosciences of California (PACB) has announced a significant leadership change, with Mark Van Oene, the current COO, being appointed as the new President and CEO, effective…
Aug 5, 2026 Corporate Catalyst Bearish Impact 95
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate
Pacific Biosciences (PACB) announced its Q2 earnings, reporting an adjusted EPS of $(0.14) and sales of $39.007 million. Both figures fell short of analyst consensus estimates, wit…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.